Together, PRIMA-1 and SHetA2 had additive effects and prevented ovarian cancer tumor growth in 67% of mice [32], indicating that this combination may be effective as a maintenance therapy for ovarian cancer patients. Here, PRIMA1 is linked to ovarian carcinoma.